{"id":15,"date":"2026-03-04T10:18:49","date_gmt":"2026-03-04T10:18:49","guid":{"rendered":"https:\/\/medi-first-research.de\/?page_id=15"},"modified":"2026-03-18T10:32:31","modified_gmt":"2026-03-18T10:32:31","slug":"evidenzsystem","status":"publish","type":"page","link":"https:\/\/medi-first-research.de\/en\/evidenzsystem\/","title":{"rendered":"Evidence System"},"content":{"rendered":"
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Our evidence system.<\/h1>\n<\/div>\n\n\n\n

In cannabinoid-based therapy, evidence is part of development - not an after-the-fact proof.<\/strong><\/p>\n

That is why Medi First R&D works with standardized evidence pathways to bring target profiles (TPP), formulation, and clinical application together within a consistent criteria logic.<\/p>\n<\/div>

<\/div><\/div>Request a methodology briefing<\/span><\/a>\n
\n\t

Note: Provision after qualification, possibly NDA-based.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Methodological validation: from the clinical target profile to robust evidence.<\/h1>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

The logic of reverse engineering<\/h2>\n<\/div>\n\n\n\n\n
\n\t

We start with the clinical requirement. Via a Target Product Profile (TPP), parameters for efficacy, tolerability, dosability, and use are defined - before formulation and prototyping begin. This keeps development traceable, comparable, and consistently oriented toward real clinical endpoints.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

The evidence pipeline: a multimodal approach<\/h2>\n<\/div>\n\n\n\n\n
\n\t

We generate evidence along a structured pipeline, tailored to the question and development phase:<\/p>\n<\/div>\n\n\n\n

<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
\"\"
<\/span><\/div>
\n

01 Preclinical validation<\/h3>\n

Characterization of biochemical profiles and suitable preclinical models to test defined hypotheses.<\/div><\/div><\/div>

<\/span><\/div>
\n

02 Observational research \/ Real-World Data (RWD) & Real-World Evidence (RWE)<\/h3>\n

Analysis of anonymized care data and outcomes to assess tolerability, use, and adherence under real-world conditions.<\/div><\/div><\/div>

<\/span><\/div>
\n

03 Clinical protocolization (e.g., non-interventional studies, indication-specific protocols)<\/h3>\n

Transfer of insights into standardized application and observation protocols that support clinical decision-making processes.<\/div><\/div><\/div><\/div>\n

\n\t

Our basis for iterative optimization in the evidence loop: evidence generation (preclinical \u00b7 observational \u00b7 clinical).<\/h3>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Integrated data loop through vertical integration.<\/h2>\n<\/div>\n\n\n\n\n
\n\t

A key feature of Medi First R&D is the direct connection to the group\u2019s own care network. The closed-loop approach makes it possible to feed anonymized data from clinical practice back into research in a structured way.<\/p>\n<\/div>\n\n\n\n

<\/div><\/div>
1<\/span><\/div>

<\/h4>Input<\/strong>\u00a0patterns in tolerability, use, or efficacy from everyday care<\/div><\/div>
2<\/span><\/div>

<\/h4>Response:<\/strong>\u00a0adjustment of formulation\/delivery or target-profile parameters (TPP)<\/div><\/div>
3<\/span><\/div>

<\/h4>Output:<\/strong>\u00a0updated protocols, standards, and implementation logic back into care<\/div><\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t

Data integrity as an ethical and professional obligation.<\/h2>\n<\/div>\n\n\n\n\n
\n\t

Our evidence system operates under strict adherence to international standards. All data collection is GDPR-compliant and anonymized; our processes are documented and quality-assured. The goal is evidence that is scientifically traceable, regulatorily compatible, and implementable within care processes.<\/p>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \"\"\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div><\/div>
<\/div>
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t

Collaboration<\/h2>\n<\/div>\n\n\n\n\n
\n\t

We support hospitals, universities, and industry partners in planning and executing evidence-based projects - from scoping and protocol design to analysis.<\/p>\n<\/div>\n\n\n\n

<\/div><\/div>Inquire about collaboration<\/span><\/a>\n
\n\t

Note: Information on this website is intended for professional and collaboration partners. It does not constitute medical advice in any way.<\/p>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Unser Evidenzsystem In der cannabinoidbasierten Therapie ist Evidenz Teil der Entwicklung \u2013 nicht der nachgelagerte Nachweis. Deshalb arbeitet Medi First R&D mit standardisierten Evidenzpfaden, um Zielprofile (TPP), Formulierung und klinische...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-15","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/15","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/comments?post=15"}],"version-history":[{"count":56,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/15\/revisions"}],"predecessor-version":[{"id":1148,"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/pages\/15\/revisions\/1148"}],"wp:attachment":[{"href":"https:\/\/medi-first-research.de\/en\/wp-json\/wp\/v2\/media?parent=15"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}